Inaugural Northwest Gynecological Cancer Symposium brings together scientists studying ovarian, cervical and endometrial cancers
Dec. 6, 2017
| By Rachel Tompa / Fred Hutch News Service
Monday, cancer researchers from around the Pacific Northwest gathered at Fred Hutchinson Cancer Research Center to discuss their latest efforts to better prevent, detect and treat cancers of the female reproductive tract in the inaugural Northwest Gynecological Cancer Symposium.
An immunotherapy technology developed by Dr. Brian Till with Dr. Oliver Press at Fred Hutchinson Cancer Research Center has been licensed by Mustang Bio Inc., a subsidiary of the biopharmaceutical company Fortress Biotech Inc. The exclusive, worldwide license, announced Sept. 14 by Mustang Bio, will allow a new type of CAR (chimeric antigen receptor) T-cell therapy to be tested in a clinical trial as a treatment for B-cell non-Hodgkin lymphomas. The novel immunotherapy targets CD20, a protein marker on cancer cells in lymphoma.